专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2002228435B2 Graft rejection inhibitors 未知
公开(公告)号：AU2002228435B2
公开(公告)日：2005-03-10
申请号：AU2002228435
申请日：2002-02-05
申请人： JAPAN TOBACCO INC
发明人： SUZUKI SEIICHI , ISOBE MITSUAKI
IPC分类号： A61K38/02 , A61K31/7105 , A61K31/711 , A61K38/00 , A61K39/395 , A61K45/00 , A61P37/06 , C07K16/28 , A61K045/00 , A61K031/573 , A61K038/13 , A61K031/7056 , A61K031/436 , A61K031/365 , A61K031/16 , A61K038/02 , A61K039/395 , A61K031/711 , A61K031/7105 , A61P037/06 , A61K031/52
摘要： It was found that antibodies against AILIM (also known as ICOS and 8F4) and AILIM-Ig have significant therapeutic effects towards the suppression and prevention of graft rejection. Graft rejection is a serious problem associated with tissue or organ transplantation (allotransplantation or xenotransplantation), performed to treat various organ failures (liver, heart, lung, kidney, pancreas, etc.) .

2. 发明申请

US20040132669A1 Glycopyranosyloxypyrazole derivatives and medicinal use thereof 有权
标题翻译：糖吡喃糖氧吡唑衍生物及其药用
公开(公告)号：US20040132669A1
公开(公告)日：2004-07-08
申请号：US10468454
申请日：2004-02-19
发明人： Toshihiro Nishimura , Nobuhiko Fushimi , Hideki Fujikura , Kenji Katsuno , Yoshimitsu Komatsu , Masayuki Isaji
IPC分类号： C07H017/02 , A61K031/7056
CPC分类号： C07H15/203 , C07H17/02
摘要： The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: 1 wherein one of Q and T represents a group represented by the general formula: 2 while the other represents a lower alkyl group or a halo(lower alkyl) group; R1 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkenyl group, a cyclic lower alkyl group, etc.; R2 represents a hydrogen atom, an optionally substituted lower alkyl group, a lower alkoxy group, a lower alkenyl group, a cyclic lower alkyl group, a cyclic lower alkoxy group, etc., which exert an excellent inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutically acceptable salts thereof or prodrugs thereof, production intermediates thereof and pharmaceutical uses thereof.
摘要翻译：本发明提供由以下通式表示的吡喃葡萄糖氧吡唑衍生物：其中Q和T之一表示由通式表示的基团，而另一个代表低级烷基或卤代（低级烷基）基团; R 1表示氢原子，任选取代的低级烷基，低级烯基，环状低级烷基等; R 2表示在人SGLT2中具有优异的抑制活性的氢原子，任选取代的低级烷基，低级烷氧基，低级烯基，环状低级烷基，环状低级烷氧基等因此可用作预防或治疗与高血糖相关的疾病如糖尿病，糖尿病并发症或肥胖症的药物，其药学上可接受的盐或其前药，其制备中间体及其药学用途。

3. 发明申请

US20040033964A1 Texaphyrin coordination compounds and uses thereof 失效
标题翻译：特拉法林配位化合物及其用途
公开(公告)号：US20040033964A1
公开(公告)日：2004-02-19
申请号：US10415916
申请日：2003-05-01
发明人： Darren Magda , Dale Miles , Nikolay Gerasimchuk , Cheryl Lepp
IPC分类号： A61K031/7056 , A61K031/555
CPC分类号： C07D487/22 , A61K31/00 , A61K31/555 , A61K41/0028 , A61K41/0038 , A61K41/0076 , C07D519/00 , C08G61/12
摘要： Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed.
摘要翻译：公开了可用于治疗动脉粥样化，肿瘤和其它肿瘤组织的新型配位聚合物及其药物制剂，以及对诱导靶向氧化应激有反应的其它条件。

4. 发明申请

US20040023891A1 Agents for neutron capture therapy 审中-公开
标题翻译：中子捕获治疗药物
公开(公告)号：US20040023891A1
公开(公告)日：2004-02-05
申请号：US10362964
申请日：2003-02-25
发明人： Tarak D Mody , Jonathan L Sessler , Stuart W Young
IPC分类号： A61K031/7056 , A61K031/555 , A61K031/409
CPC分类号： C07D487/22 , A61K31/355 , A61K41/009
摘要： Compounds, pharmaceutical formulations and methods for use in neutron capture therapy are provided, useful for treating diseases characterized by neoplastic tissue and arteriosclerosis.
摘要翻译：提供了用于中子捕获治疗的化合物，药物制剂和方法，其可用于治疗以肿瘤组织和动脉硬化为特征的疾病。

5. 发明申请

US20040018997A1 Inactivation of West Nile virus and malaria using photosensitizers 有权
标题翻译：使用光敏剂灭活西尼罗病毒和疟疾
公开(公告)号：US20040018997A1
公开(公告)日：2004-01-29
申请号：US10358073
申请日：2003-02-03
发明人： Heather Reddy , Raymond P. Goodrich
IPC分类号： A61K031/7056
CPC分类号： A61L2/10 , A61K41/0019 , A61K41/0057 , A61L2/0011 , A61L2/0082 , A61L2/0088 , A61L2/08 , A61M1/0213 , A61M1/3681 , A61M1/3683 , A61M1/3693 , A61M2205/123
摘要： Methods and apparatuses are provided for inactivation of microorganisms in fluids or on surfaces. Preferably the fluids contain blood or blood products and comprise biologically active proteins. Preferred methods include the steps of adding an effective, non-toxic amount of a photosensitizer to a fluid and exposing the fluid to photoradiation sufficient to activate the photosensitizer whereby microorganisms are inactivated.
摘要翻译：提供了用于灭活流体或表面上的微生物的方法和装置。优选地，流体含有血液或血液制品并且包含生物活性蛋白质。优选的方法包括以下步骤：将有效的无毒量的光敏剂加入到流体中，并使流体暴露于足以激活光敏剂的光热释放剂中，从而使微生物灭活。

6. 发明申请

US20040014696A1 Specificity in treatment of diseases 审中-公开
标题翻译：治疗疾病的特异性
公开(公告)号：US20040014696A1
公开(公告)日：2004-01-22
申请号：US10343529
申请日：2003-07-11
发明人： Johnson Lau , Zhi Hong , Chin-chung Lin
IPC分类号： A61K031/7056 , A61K031/52
CPC分类号： A61K31/7056 , A61K31/52 , C07H19/056
摘要： A drug is modified by covalently coupling a blocking group to the drug via a nitrogen atom in the blocking group. The blocking group in the modified drug prevents metabolic conversion and sequestration of the drug in non-target cells, and the blocking group is enzymatically removed in the target cell. Particularly contemplated advantages of presented compounds and methods include reduction of cytotoxicity by inhibition of metabolic conversion to potentially cytotoxic metabolites, reduction of dosages of drugs by reduction of sequestration into non-target cells, and increase of selectivity of a drug.
摘要翻译：通过阻断基团中的氮原子共价将阻断基团与药物偶联来修饰药物。改性药物中的阻断基团可防止非靶细胞中药物的代谢转化和螯合，并且阻断基团在靶细胞中酶促去除。所提出的化合物和方法的特别考虑的优点包括通过抑制代谢转化为潜在的细胞毒性代谢物来减少细胞毒性，通过减少封存到非靶细胞中减少药物的剂量以及增加药物的选择性。

7. 发明申请

US20030104007A1 Pseudopterosin compounds of Symbiodinium spp isolated from Pseudopterogorgia elisabethae 审中-公开
标题翻译：从seud opter p p p p of of。。。。。。。。。。。。
公开(公告)号：US20030104007A1
公开(公告)日：2003-06-05
申请号：US10264026
申请日：2002-10-04
发明人： Robert S. Jacobs , Laura Mydlarz , Russell G. Kerr
IPC分类号： A61K035/80 , A61K031/7056 , C07H019/00
CPC分类号： A61K31/704 , A61K31/015 , A61K31/05 , A61K31/122 , C07H15/24 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/419 , Y02A50/491
摘要： Disclosed herein are pseudopterosin compounds obtained from Symbiodinium spp. symbionts. Also disclosed are methods of obtaining, isolating, purifying or preparing at least one pseudopterosin compound comprising obtaining, isolating, purifying or preparing the pseudopterosin compound from at least one Symbiodinium spp. symbiont. In preferred embodiments, the host is Pseudopterogorgia, preferably, P. elisabethae. As disclosed, preferred pseudopterosin compounds and pseudopterosin compositions are of non-animal origin, substantially free of animal impurities, or both. Treatment methods using the pseudopterosin compounds and compositions are also disclosed.
摘要翻译：本文公开的是从共生ium属物种获得的伪蝶呤化合物。共生体。还公开了获得，分离，纯化或制备至少一种假翅目蛋白化合物的方法，包括从至少一种共莠ium属获得，分离，纯化或制备假opter in素化合物。共生体在优选的实施方案中，宿主是假猕猴（Pseudopterogorgia），优选疟原虫（P. elisabethae）。如所公开的，优选的假翅目蛋白化合物和假蝇草素组合物是非动物来源的，基本上不含动物杂质，或两者。还公开了使用假蝇蕈碱化合物和组合物的治疗方法。

8. 发明申请

US20030073647A1 Crystaline clindamycin free base 审中-公开
公开(公告)号：US20030073647A1
公开(公告)日：2003-04-17
申请号：US10227901
申请日：2002-08-26
发明人： Robert S. Chao , Michael Hawley , Lisa M. Reeder , Donald P. Jones
IPC分类号： A61K031/7056 , C07H015/16
CPC分类号： C07H13/10 , C07H15/16 , C07H15/26
摘要： A processes for preparing crystalline clindamycin free base is provided.

9. 发明申请

US20020198157A1 Galectin recognized photosensitizers for photodynamic therapy 失效
标题翻译： Galectin认可光敏剂用于光动力疗法
公开(公告)号：US20020198157A1
公开(公告)日：2002-12-26
申请号：US10141241
申请日：2002-05-07
发明人： Ravindra K. Pandey , Thomas J. Dougherty
IPC分类号： A61K031/7056 , A61K031/555 , A61K031/409 , C07D487/22
CPC分类号： C07H15/18 , C07H15/26 , C07H23/00
摘要： Purpurin-carbohydrate conjugates and their method of preparation and use for treatment of cancer cells. The conjugates have the general formula: 1 where R6 and R7 taken together are nullNR11 or are independently nullOR11 where at least one R11 is preferably a mono or polysaccharide moiety and R1-R8 are various groups formed from carbon and hydrogen and optionally oxygen and nitrogen where R3 and R4 may together form a covalent bond.
摘要翻译：紫杉醇 - 碳水化合物缀合物及其制备和用于治疗癌细胞的方法。缀合物具有以下通式：其中R 6和R 7一起为= NR 11或独立地为-OR 11，其中至少一个R 11优选为单糖或多糖部分，并且R 1 -R 8为由碳和氢以及任选的氧和氮形成的各种基团其中R3和R4可以一起形成共价键。

10. 发明申请

US20020142971A1 Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols 失效
标题翻译： 2-（4-羟基 - 苯基）-3-甲基-1- [4-（2-氨基-1-基 - 乙氧基） - 苄基] -1H-吲哚-5-醇的吡喃葡糖苷偶联物
公开(公告)号：US20020142971A1
公开(公告)日：2002-10-03
申请号：US10087349
申请日：2002-03-01
申请人： American Home Products Corporation
发明人： Chris P. Miller , Michael D. Collini , Bach D. Tran , Anita Wai-Yin Chan , Arkadiy Z. Rubezhov
IPC分类号： C07H017/02 , C07D43/02 , A61K031/7056 , A61K031/55 , A61K031/454
CPC分类号： C07H17/02
摘要： This invention provides tissue selective estrogens of formula I having the structure 1 wherein: R1 and R2 are independently, hydrogen, alkyl chain of 1-6 carbon atoms, benzyl, acyl of 2-7 carbon atoms, benzoyl, 2 X is hydrogen, alkyl of 1-6 carbon atoms, CN, halogen, trifluoromethyl, or thioalkyl of 1-6 carbon atoms; nnull1-3; with the proviso that at least one of R1 or R2 are not hydrogen, alkyl chain of 1-6 carbon atoms, benzyl, acyl of 2-7 carbon atoms, or benzoyl; or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供了具有以下结构的式I的组织选择性雌激素：其中：R 1和R 2独立地是氢，1-6个碳原子的烷基链，苄基，2-7个碳原子的酰基，苯甲酰基，X是氢， -6个碳原子，CN，卤素，三氟甲基或1-6个碳原子的硫代烷基; n = 1-3; 条件是R1或R2中的至少一个不是氢，1-6个碳原子的烷基链，苄基，2-7个碳原子的酰基或苯甲酰基; 或其药学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式